You searched for "VEGF"
Effect of minor trauma in eyes with previously undiagnosed angioid streaks
1 April 2014
| Balini Balasubramaniam
|
EYE - Cataract, EYE - Cornea, EYE - General, EYE - Glaucoma, EYE - Imaging, EYE - Neuro-ophthalmology, EYE - Oculoplastic, EYE - Oncology, EYE - Orbit, EYE - Paediatrics, EYE - Pathology, EYE - Refractive, EYE - Strabismus, EYE - Vitreo-Retinal
Angioid streaks (AS) may be associated with pseudoxanthoma elasticum (PXE), Paget’s disease, haemoglobulinopathies, Ehlers-Danlos Syndrome or abetalipoproteinaemia. Histopathology showed retinal pigment epithelium (RPE) and choriocapillaris loss, elastic fibre degeneration, calcium deposition, active choroidal neovascular membrane (CNVM) and vascular endothelial growth...
Update on emerging therapies for age-related macular degeneration
4 December 2023
| Rod McNeil
|
EYE - Vitreo-Retinal
The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...
Macula re-attachment following intravitreal ranibizumab in rhegmatogenous retinal detachment
Ranibizumab (Lucentis) is a vascular endothelial growth factor inhibitor (anti-VEGF) used for treatment of choroidal neovascular membrane [1]. We report a case where macula off inferior rhegmatogenous retinal detachment was misdiagnosed as wet age-related macular degeneration (AMD) and three intravitreal...A patient report of pseudoxanthoma elasticum, angioid streaks and choroidal neovascularisation
1 October 2015
| Zaria Ali, Mohammed Alarbi, Salwa Abugreen
|
EYE - Cataract, EYE - Cornea, EYE - General, EYE - Glaucoma, EYE - Imaging, EYE - Neuro-ophthalmology, EYE - Oculoplastic, EYE - Oncology, EYE - Orbit, EYE - Paediatrics, EYE - Pathology, EYE - Refractive, EYE - Strabismus, EYE - Vitreo-Retinal
Angioid streaks (AS) on their own do not cause many problems, with the majority of patients remaining asymptomatic [1]. However, once choroidal neovascularisation (CNV) occurs, the visual prognosis of the patient rapidly declines [2]. Treatment is imperative to try and...
Intravitreal bevacizumab vs. ranibizumab in the treatment of macular oedema due to BRVO
This is a randomised, prospective, non-inferiority trial of 75 patients with macular oedema due to a branch retinal vein occlusion (BRVO) who received intravitreal injections of ranibizumab or bevacizumab after 1:1 block randomisation. This study is to measure the difference...OCTA in diabetic macular oedema treated with intravitreal aflibercept (DOCTA Study)
3 April 2024
| Sofia Rokerya
|
EYE - Vitreo-Retinal
Central vision loss due to diabetic macular oedema (DME) can be attributed not only to presence of the macular oedema itself but also, in some cases, to alterations of the foveal avascular zone (FAZ). The DOCTA trial was a longitudinal,...
Epidemiology of ocular cancer in Cali
The aim of this study was to describe the population trends of incidence and survival rates of ocular cancer in Cali, Columbia. Data was retrieved from the Registro Poblacion de Cancer de Cali (RPCC, i.e. Population Cancer Registry of Cali)...Moorfields: Pregnancy considerations in women with eye disease: a day of obstetrics for ophthalmologists
10 March 2025
Ophthalmic conditions are common in women of childbearing age, and treatments for these are evolving at a fast pace. When these women become pregnant, a common source of anxiety is both the potential continuation of these medications, as well as...
Moorfields cataract, medical retina and disc assessment
31 March 2025
The Cataract/medical retina/ disc assessment short course has been designed to meet the training needs of band 6’s and 7s who wish to develop their knowledge and skills in disease recognition, management and intervention of cataract, medical retina and disc...
Initiatives in macular service provision
1 December 2015
| Rod McNeil
|
EYE - Vitreo-Retinal
A report from Monitor in October 2015 identifies good practices that will realise most of the potential productivity gain in elective care available to NHS hospitals. These include: stratifying patients by risk and creating low-complexity pathways for lower-risk patients (tailoring...
How many injections in nAMD: ranibizumab vs. aflibercept
1 April 2017
| Eulee Seow
|
EYE - Vitreo-Retinal
Intravitreal anti-VEGF injections make up a large proportion of the workload in ophthalmology clinics. Since the introduction of aflibercept with eight weekly injections there has been an option to use a treatment which may require less treatment, with potential cost...
ANGPTL-4 inhibition reduces inflammation in diabetic retinopathy
1 June 2018
| Graham Wallace
|
EYE - Vitreo-Retinal
Diabetic retinopathy (DR) is the most common cause of blindness in working-age humans, and numbers are rising due to increased cases of type 2 diabetes (T2D). T2D is associated with increased obesity and dyslipidaemia, which is a major risk factor...